The strong PFS and ORR data support potential accelerated approval; traders should monitor for NDA submission in H2 2026 and upcoming data presentation at a major medical conference. This could be a catalyst for significant upside given the lack of effective treatments in metastatic uveal melanoma.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 13 $32.82entry
- T+1 · 7mo ago −1.43%α −2.64% · $32.35
- T+5 · 7mo ago +2.38%α −0.92% · $33.60
- T+20 · 6mo ago −14.29%α −22.02% · $28.13
- T+60 · 4mo ago +15.66%α +6.74% · $37.96
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
IDEAYA Biosciences announced positive Phase 2/3 clinical trial results for darovasertib in combination with crizotinib in first-line HLA-A*02:01-negative metastatic uveal melanoma, showing a 58% reduction in risk of progression and significantly improved median progression-free survival (6.9 vs 3.1 months). The company plans to submit a New Drug Application (NDA) in the second half of 2026.
Key Facts
- Darovasertib combination met primary endpoint of statistically significant improvement in median PFS (6.9 months vs 3.1 months) with hazard ratio of 0.42 (p < 0.0001)
- ORR was 37.1% in the darovasertib arm vs 5.8% in the investigator choice therapy arm (p < 0.0001)
- 5 complete responses observed in darovasertib arm, none in control arm
- Median DOR was 6.8 months in the darovasertib arm
- OS data not mature but early trend favoring darovasertib combination
- Safety profile manageable with Grade 3+ adverse events including diarrhea, syncope, and hypotension
- NDA submission targeted for second half of 2026
Financial Impact
Potential blockbuster approval in a high-unmet-need orphan indication with no current standard of care; market opportunity estimated at $500M+ annual peak sales
Risk Factors
- OS data not mature, creating uncertainty about overall survival benefit
- FDA may require confirmatory trial post-approval
- Competition from other targeted therapies in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-151893 |
| Document: 0001193125-26-151893-index-headers.html | 0001193125-26-151893 |
| Document: 0001193125-26-151893-index.html | 0001193125-26-151893 |
| Document: 0001193125-26-151893.txt | 0001193125-26-151893 |
Track record
13 reports on IDYA
1 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +10.76% at T+20 after the Oct 6, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
- Oct 6, 20265w ago 144 Bearish 6/10 Entry $36.26 to $33.86 Now $30.36 +16.27% ▲ +6.62% +5.64% vs SPY
- Aug 4, 202614w ago 8-K Neutral 4/10 Entry $36.11 to $36.84 Now $30.36 −15.92% ▲ +2.02% +2.12% vs SPY
- Jun 23, 202620w ago 8-K Neutral 2/10 Entry $36.28 to $36.17 Now $30.36 −16.32% ▼ −0.30% −2.01% vs SPY
- Jun 10, 202622w ago 8-K Bearish 6/10 Entry $28.84 to $31.26 Now $30.36 −5.27% ▼ −8.39% −7.96% vs SPY
- Jun 9, 202622w ago 424B5 Bearish 6/10 Entry $27.60 to $30.57 Now $30.36 −10.00% ▼ −10.76% −7.33% vs SPY
- Jun 8, 202623w ago 424B5 Bearish 6/10 Entry $28.07 to $30.23 Now $30.36 −8.16% ▼ −7.70% −5.28% vs SPY
- Jun 3, 202623w ago 8-K Neutral 4/10 Entry $28.40 to $27.60 Now $30.36 +6.90% ▼ −2.82% +1.00% vs SPY
- May 5, 202627w ago 8-K Neutral 2/10 Entry $28.74 to $28.12 Now $30.36 +5.64% ▼ −2.16% −3.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers